Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kendra L Sweet

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
International Journal of Hematologic Oncology|November 9, 2018
Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectivesChetasi Talati, Kendra L Sweet
Critical Reviews in Oncology/Hematology|August 24, 2013
The one-two punch: combination treatment in chronic myeloid leukemiaKendra L Sweet, Lori A Hazlehurst, Javier Pinilla-Ibarz
Oncotargets and Therapy|August 30, 2016
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedJavier Pinilla-Ibarz, Kendra L Sweet, Gabriela M Corrales-Yepez, et al.
British Journal of Haematology|October 13, 2025
First-line tagraxofusp induces durable responses with prolonged survival in adults younger than 50 years with blastic plasmacytoid dendritic cell neoplasm: Post hoc analysis of a phase 2 trialAnthony S Stein, Andrew A Lane, Kendra L Sweet, et al.
Cancer|August 9, 2022
Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlatesAndrew T Kuykendall, Qianxing Mo, David A Sallman, et al.
Cancer|January 5, 2026
Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasmMarina Konopleva, Naveen Pemmaraju, Kendra L Sweet, et al.
Leukemia & Lymphoma|March 11, 2025
Efficacy of first-line tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with prior or concomitant hematologic malignancy: subgroup analysis of a pivotal trialNaveen Pemmaraju, Marina Konopleva, Kendra L Sweet, et al.
Annals of Hematology|September 7, 2024
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemiaAkriti G Jain, Virginia O Volpe, Chen Wang, et al.
Leukemia|July 31, 2020
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)Seongseok Yun, Susan M Geyer, Rami S Komrokji, et al.
Leukemia Research|April 29, 2019
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)David A Sallman, Rami S Komrokji, Kendra L Sweet, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
International Journal of Hematologic Oncology|November 9, 2018
Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectivesChetasi Talati, Kendra L Sweet
Critical Reviews in Oncology/Hematology|August 24, 2013
The one-two punch: combination treatment in chronic myeloid leukemiaKendra L Sweet, Lori A Hazlehurst, Javier Pinilla-Ibarz
Oncotargets and Therapy|August 30, 2016
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedJavier Pinilla-Ibarz, Kendra L Sweet, Gabriela M Corrales-Yepez, et al.
British Journal of Haematology|October 13, 2025
First-line tagraxofusp induces durable responses with prolonged survival in adults younger than 50 years with blastic plasmacytoid dendritic cell neoplasm: Post hoc analysis of a phase 2 trialAnthony S Stein, Andrew A Lane, Kendra L Sweet, et al.
Cancer|August 9, 2022
Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlatesAndrew T Kuykendall, Qianxing Mo, David A Sallman, et al.
Cancer|January 5, 2026
Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasmMarina Konopleva, Naveen Pemmaraju, Kendra L Sweet, et al.
Leukemia & Lymphoma|March 11, 2025
Efficacy of first-line tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with prior or concomitant hematologic malignancy: subgroup analysis of a pivotal trialNaveen Pemmaraju, Marina Konopleva, Kendra L Sweet, et al.
Annals of Hematology|September 7, 2024
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemiaAkriti G Jain, Virginia O Volpe, Chen Wang, et al.
Leukemia|July 31, 2020
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)Seongseok Yun, Susan M Geyer, Rami S Komrokji, et al.
Leukemia Research|April 29, 2019
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)David A Sallman, Rami S Komrokji, Kendra L Sweet, et al.
Pageof 3